Jolanda Howe Sells 750 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 750 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $32,115.00. Following the completion of the transaction, the senior vice president now owns 2,926 shares of the company’s stock, valued at $125,291.32. This represents a 20.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Jolanda Howe also recently made the following trade(s):

• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.10, for a total value of $117,750.00.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $42.00 on Friday. The stock’s 50 day moving average price is $42.93 and its two-hundred day moving average price is $40.62. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -20.79 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. During the same period last year, the company posted ($0.57) earnings per share. The business’s quarterly revenue was up 89.4% on a year-over-year basis. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Leerink Partners increased their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $57.10.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC acquired a new stake in Mirum Pharmaceuticals in the third quarter valued at approximately $28,913,000. Loomis Sayles & Co. L P bought a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $19,473,000. Clearbridge Investments LLC increased its stake in Mirum Pharmaceuticals by 165.5% during the 2nd quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after purchasing an additional 436,349 shares in the last quarter. State Street Corp raised its holdings in Mirum Pharmaceuticals by 19.9% during the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after buying an additional 297,511 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new position in shares of Mirum Pharmaceuticals in the third quarter valued at $10,136,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.